The abstract is read at the publisher; the summary is JClub's.
In the US observational cohort (Jan 2022–Jun 2025), 6-month CAB-LA PrEP abandonment was 11.9% for women versus 18.1% for DO-PrEP, with aRR=0.68 (95% CI 0.62–0.74).
- Why it matters: National estimates of CAB-LA PrEP abandonment are needed to guide implementation after FDA approval and to identify who is most likely to stop filling prescriptions.
- What they did: Using IQVIA Longitudinal Prescription data, the study compared 6-month abandonment risk after an index CAB-LA or DO-PrEP prescription during 2022–2024, estimating adjusted risk ratios via multivariable modified Poisson regression.
- The result: CAB-LA prescribing rose from 4,645 individuals in 2022 to 23,378 in 2024 and 25,018 in Jan–Jun 2025, and abandonment risk differed by sex and regimen, implying sex-specific uptake barriers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.